IP Library Granted Patent US 8,921,534
Granted Patent B2
US 8,921,534 · App. 10/317,821 · Granted Dec 30, 2014

Enhancement of the immune response using CD36-binding domain

Inventors: William I. Cox (East Greenbush, NY); Jeannine P. Alexander (Clifton Park, NY); Scott Goebel (Ballston Spa, NY)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,534
App. No.
10/317,821
Granted
Dec 30, 2014
Kind
B2
Abstract

The invention relates to reagents and methods for enhancing an immune response using CD36 binding region/antigen hybrid polypeptides or polynucleotides encoding the hybrid polypeptides.

Claims (15)

1. An isolated nucleic acid molecule encoding an immunogenic chimeric polypeptide, the nucleic acid molecule comprising at least a first nucleic acid sequence positioned upstream of and in frame with a second nucleic acid sequence, wherein:

the first nucleic acid sequence encodes two domains comprising the amino acid sequence CSVTCG (SEQ ID NO: 11) separated by a spacer region of about 11 amino acids; and,

the second nucleic acid sequence encodes at least one tumor antigen or an antigen derived from an infectious agent.

2. The isolated nucleic acid molecule of claim 1 wherein the spacer region has a beta sheet conformation.

3. The isolated nucleic acid molecule of claim 2 wherein the spacer amino acids comprise DGVITRIRLCN (SEQ ID NO: 1).

4. The isolated nucleic acid molecule of claim 1 further encoding a signal nucleic acid sequence consisting essentially of an endoplasmic reticulum signal sequence and a signal peptidase cleavage sequence.

5. The isolated nucleic acid molecule of claim 1 wherein the infectious agent is selected from the group consisting of a bacterium, a parasite, a virus, a fungus, and a cancerous cell.

6. The isolated nucleic acid molecule of claim 5 wherein second nucleic acid sequence encodes a gp120 polypeptide or immunogenic fragment thereof.

7. The isolated nucleic acid molecule of claim 1 or 5 further comprising a transcriptional regulatory region operably linked to at least one of the nucleic acid sequences.

8. The isolated nucleic acid molecule of claim 7 wherein said transcriptional control region is the CMV promoter.

9. An immunogenic composition for generating an immune response in a host, the composition comprising a nucleic acid molecule of claim 1 or 5 .

10. An immunogenic composition for generating an immune response in a host, the composition comprising a nucleic acid molecule of claim 6 .

11. An immunogenic composition for generating an immune response in a host, the composition comprising a nucleic acid molecule of claim 7 .

12. An immunogenic composition for generating an immune response in a host, the composition comprising a nucleic acid molecule of claim 8 .

13. The nucleic acid molecule of claim 1 wherein the first nucleic acid sequence encodes at least the amino acid sequence of SEQ ID NO.: 10.

Assignments (2)
CHANGE OF NAME Recorded Mar 28, 2014
From: AVENTIS PASTUER LIMITED
To: SANOFI PASTEUR LIMITED
Reel/Frame 032555/0483 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2014
From: COX, WILLIAM I; ALEXANDER, JEANINE P; GOEBEL, SCOTT
To: AVENTIS PASTUER LIMITED
Reel/Frame 032560/0053 →
Continuity (2)
Provisional Application 60341771 · Dec 12, 2001
Related Publication 20040241652A1 · Dec 2, 2004